Shingles protection for adults with immunocompromise

+Practice
In print
Vaccines

Shingles protection for adults with immunocompromise

Ballpoint pen

Mary Nowlan

Vaccines-Figure

This article details the recent widening of eligibility for funded herpes zoster vaccine to immunocompromised adults

Key points, Herpes zoster is a painful and potentially severe condition. Highest incidence of zoster is seen in those with immunocompromise and/or older age. , Pract Green w Pale Yellow
References
  • Bhavsar A, Lonnet G, Wang C, et al. Increased risk of herpes zoster in adults ≥50 years old diagnosed with COVID-19 in the United States. Open Forum Infect Dis 2022;9(5):ofac118.
  • Cunningham AL, Lal H, Kovac M, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. NEJM 2016;375(11):1019–32.
  • Goud R, Lufkin B, Duffy J, et al. Risk of Guillain-Barre syndrome following recombinant zoster vaccine in Medicare beneficiaries. JAMA Intern Med 2021;181(12):1623–30.
  • Izurieta HS, Wu X, Forshee R, et al. Recombinant zoster vaccine (Shingrix): Real-world effectiveness in the first 2 years post-licensure. Clin Infect Dis 2021;73(6):941–48.
  • Lal H, Cunningham AL, Godeaux O, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. NEJM 2015;372(22):2087–96.
  • Marijam A, Vroom N, Bhavsar A, et al. Systematic literature review on the incidence of herpes zoster in populations at increased risk of disease in the EU/EEA, Switzerland, and the UK. Infect Dis Ther 2024;13(5):1083–104.
  • Oostvogels L, Heineman TC, Johnson RW, et al. Medical conditions at enrolment do not impact efficacy and safety of the adjuvanted recombinant zoster vaccine: a pooled post-hoc analysis of two parallel randomized trials. Hum Vacc Immunother 2019;15(12):2865–72.
  • Racine E, Gilca V, Amini R, et al. A systematic literature review of the recombinant subunit herpes zoster vaccine use in immunocompromised 18-49-year-old patients. Vaccine 2020;38(40):6205–14.
  • Strezova A, Diez-Domingo J, Al Shawafi K, et al. Long-term protection against herpes zoster by the adjuvanted recombinant zoster vaccine: Interim efficacy, immunogenicity, and safety results up to 10 years after initial vaccination. Open Forum Infect Dis 2022;9(10):ofac485.
  • Tavares-Da-Silva F, Co MM, Dessart C, et al. Review of the initial post-marketing safety surveillance for the recombinant zoster vaccine. Vaccine 2020;38(18):3489–500.
  • Walia A, Sun Y, Acharya NR. Risk of herpes zoster ophthalmicus recurrence after recombinant zoster vaccination. JAMA Ophthalmol 2024;142(3):249–56.